{"url_path":"/sec/orka/8-k/2026-06-04/item-5-07","section_key":"item-5-07","section_title":"Item 5.07 ** **Submission of Matters to a Vote of Security Holders.**","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-06-04","source_url":"https://www.sec.gov/Archives/edgar/data/907654/0001213900-26-065294-index.html","accession_number":"0001213900-26-065294","cik":"0000907654","ticker":"ORKA","issuer_name":"Oruka Therapeutics, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/907654/0001213900-26-065294-index.html","primary_entity_key":"0000907654","primary_entity_name":"Oruka Therapeutics, Inc."},"word_count":353,"has_tables":true,"body_markdown":"**Item 5.07** **Submission of Matters to a Vote of Security Holders.**\n\n \n\nOn\nJune 2, 2026, Oruka Therapeutics, Inc. (the “**Company**”) held its Annual Meeting of Stockholders (the “**Annual\nMeeting**”). Set forth below is a brief description of each matter considered and voted upon at the Annual Meeting, together\nwith the final tally of the number of votes cast for or against, as well as the number of abstentions and broker non-votes as\nto each such matter. A more complete description of each matter is set forth in the Company’s definitive proxy statement for the\nAnnual Meeting filed with the Securities and Exchange Commission on April 17, 2026 (the “**Proxy Statement**”).\n\n \n\n**Proposal 1: Election\nof Directors.**\n\n \n\nThe Company’s stockholders elected each of\nthe two Class II directors proposed by the Company for election, to serve until the 2029 annual meeting of stockholders, and until their\nsuccessors are elected and have qualified. The tabulation of votes on this matter was as follows:\n\n \n\nDirector Nominee \nShares\n\nVoted For  \nShares\n\nWithheld \n\nLawrence Klein \n 43,918,579  \n 63,593 \n\nChris Martin \n 43,936,173  \n 45,999 \n\n \n\nThere were 1,267,194 broker non-votes for this\nproposal.\n\n \n\n**Proposal 2: Ratification of Independent\nAuditor Appointment.**\n\n \n\nThe Company’s stockholders ratified the appointment\nof PricewaterhouseCoopers LLP as the independent registered public accounting firm of the Company for its fiscal year ending December\n31, 2026.\n\n \n\nShares voted for: \n 45,206,297 \n\nShares voted against: \n 39,637 \n\nShares abstaining \n 3,432 \n\n \n\nThere were no broker non-votes for this proposal.\n\n \n\n**Proposal 3: Approval of the Compensation of our Named\nExecutive Officers on a Non-Binding, Advisory Basis.**\n\n \n\nThe Company’s stockholders approved, by non-binding\nadvisory vote, the compensation of our named executive officers as disclosed in the Proxy Statement. The tabulation of votes on this matter\nwas as follows:\n\n \n\nShares voted for: \n 43,033,967 \n\nShares voted against: \n 875,114 \n\nShares abstaining \n 73,091 \n\n \n\nThere were 1,267,194 broker non-votes for this\nproposal.\n\n \n\n1\n\n \n\n \n\n**SIGNATURES**\n\n \n\nPursuant to the requirements of the Securities\nExchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.\n\n \n\n \n**Oruka Therapeutics, Inc.**\n\n \n(Registrant)\n\n \n \n \n\nDate: June 4, 2026\nBy:\n/s/ Paul Quinlan\n\n \n \nName: \nPaul Quinlan\n\n \n \nTitle:\nGeneral Counsel\n\n \n\n \n\n2"}